Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.
Saved in:
| Title: | Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient. |
|---|---|
| Authors: | Meijer TG; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Department of Pathology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands., Martens JWM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Prager-van der Smissen WJC; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Verkaik NS; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands., Beaufort CM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., van Herk S; Oncode Institute, 3521 AL Utrecht, The Netherlands.; Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Robert-Finestra T; Oncode Institute, 3521 AL Utrecht, The Netherlands.; Department of Developmental Biology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Hoogenboezem RM; Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Ruigrok-Ritstier K; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Paul MW; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands., Gribnau J; Oncode Institute, 3521 AL Utrecht, The Netherlands.; Department of Developmental Biology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Bindels EMJ; Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Kanaar R; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands., Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., van Gent DC; Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands., Hollestelle A; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. |
| Source: | Cancers [Cancers (Basel)] 2024 Feb 10; Vol. 16 (4). Date of Electronic Publication: 2024 Feb 10. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2072-6694 |
|---|---|
| DOI: | 10.3390/cancers16040741 |
